1. Home
  2. ATNM vs DXLG Comparison

ATNM vs DXLG Comparison

Compare ATNM & DXLG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Actinium Pharmaceuticals Inc. (Delaware)

ATNM

Actinium Pharmaceuticals Inc. (Delaware)

HOLD

Current Price

$1.01

Market Cap

33.9M

Sector

Health Care

ML Signal

HOLD

Logo Destination XL Group Inc.

DXLG

Destination XL Group Inc.

HOLD

Current Price

$0.69

Market Cap

40.0M

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATNM
DXLG
Founded
2000
1976
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Clothing/Shoe/Accessory Stores
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
33.9M
40.0M
IPO Year
2013
1994

Fundamental Metrics

Financial Performance
Metric
ATNM
DXLG
Price
$1.01
$0.69
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
1
Target Price
$4.50
$1.50
AVG Volume (30 Days)
105.6K
102.6K
Earning Date
05-06-2026
05-28-2026
Dividend Yield
N/A
N/A
EPS Growth
14.17
N/A
EPS
N/A
N/A
Revenue
$90,000.00
$435,017,000.00
Revenue This Year
N/A
$3.85
Revenue Next Year
N/A
$4.09
P/E Ratio
N/A
N/A
Revenue Growth
11.11
N/A
52 Week Low
$0.95
$0.44
52 Week High
$1.89
$1.69

Technical Indicators

Market Signals
Indicator
ATNM
DXLG
Relative Strength Index (RSI) 36.37 57.12
Support Level $0.99 $0.62
Resistance Level $1.27 $0.82
Average True Range (ATR) 0.07 0.05
MACD -0.02 -0.00
Stochastic Oscillator 0.10 49.03

Price Performance

Historical Comparison
ATNM
DXLG

About ATNM Actinium Pharmaceuticals Inc. (Delaware)

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.

About DXLG Destination XL Group Inc.

Destination XL Group Inc is a retailer of branded and Tall men's clothing and shoes in the United States. It also sells products across the world. The company sells its products under the trade names Destination XL, DXL, DXL Men's Apparel, DXL outlets, Casual Male XL, and Casual Male XL outlets. The company has two principal operating segments: Store and Direct business. The company have two principal operating segments: company's stores and direct business.

Share on Social Networks: